Last 9.28 GBp
Change Today +0.63 / 7.23%
Volume 10.8M
OXB On Other Exchanges
Symbol
Exchange
London
OTC US
Frankfurt
As of 12:28 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

oxford biomedica plc (OXB) Snapshot

Open
8.57 GBp
Previous Close
8.65 GBp
Day High
9.32 GBp
Day Low
8.57 GBp
52 Week High
01/21/15 - 10.13 GBp
52 Week Low
04/29/14 - 1.83 GBp
Market Cap
238.1M
Average Volume 10 Days
3.8M
EPS TTM
-0.0069 GBp
Shares Outstanding
2.6B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OXFORD BIOMEDICA PLC (OXB)

Related News

No related news articles were found.

oxford biomedica plc (OXB) Related Businessweek News

No Related Businessweek News Found

oxford biomedica plc (OXB) Details

Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines for the treatment of cancer, and age-related or inherited neurodegenerative disorders and ocular diseases. Its LentiVector gene delivery technology platform targets non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease; RetinoStat that is in Phase I trial for ‘wet’ age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing TroVax that is in Phase II trial for colorectal cancer and mesothelioma; and Anti-5T4 antibody, which is in pre-clinical stage for the treatment of cancer. In addition, the company is developing MoNuDin for the treatment of motor neuron disease. It has collaborations and licensing agreements with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, and ImaginAb. Oxford BioMedica plc was founded in 1995 and is based in Oxford, the United Kingdom.

106 Employees
Last Reported Date: 05/4/14
Founded in 1995

oxford biomedica plc (OXB) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 429.0K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 260.0K GBP
Chief Business Officer and Executive Director
Total Annual Compensation: 225.0K GBP
Compensation as of Fiscal Year 2013.

oxford biomedica plc (OXB) Key Developments

Oxford BioMedica PLC Presents at Credit Suisse One-on-One Healthcare Conference, Mar-03-2015

Oxford BioMedica PLC Presents at Credit Suisse One-on-One Healthcare Conference, Mar-03-2015 . Venue: London, United Kingdom. Speakers: John Dawson, Chief Executive Officer and Director, Timothy William Watts, Chief Financial Officer, Company Secretary and Director.

Oxford BioMedica PLC expected to report Fiscal Year 2014 results on March 5, 2015. This event was calculated by Capital IQ (Created on February 27, 2015).

Oxford BioMedica PLC expected to report Fiscal Year 2014 results on March 5, 2015. This event was calculated by Capital IQ (Created on February 27, 2015).

Oxford BioMedica PLC Announces Change of Registered Address

Oxford BioMedica plc announced that the registered office address of the company has changed to: Windrush Court, Transport Way Oxford, OX4 6LT. The registered address at Companies House has been changed with immediate effect.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXB:LN 9.28 GBp +0.63

OXB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €9.75 EUR +0.201
BTG PLC 746.00 GBp +6.00
Pharming Group NV €0.36 EUR +0.014
Swedish Orphan Biovitrum AB kr94.50 SEK +2.70
Veloxis Pharmaceuticals A/S kr0.91 DKK -0.035
View Industry Companies
 

Industry Analysis

OXB

Industry Average

Valuation OXB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.5x
Price/Book 7.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXFORD BIOMEDICA PLC, please visit www.oxfordbiomedica.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.